Sign Out
UserName
Profession Email
Profession Email
|
Special Precautions
Patient with cardiac or gastrointestinal disease. Not indicated to treat hypnozoite liver stage forms of Plasmodium. Renal and hepatic impairment. Children. Pregnancy and lactation. Monitoring Parameters Monitor Hb, reticulocyte count, haptoglobin, LDH, and total bilirubin once weekly for up to 4 weeks after initiation of treatment. Assess for signs or symptoms of hypersensitivity.
|
|
Adverse Reactions
Significant: Hypersensitivity reactions (e.g. anaphylaxis, urticaria, rash, pruritus), post-treatment delayed haemolysis or haemolytic anaemia, reversible reticulocytopenia.
Blood and lymphatic system disorders: Anaemia.
Cardiac disorders: Bradycardia.
Gastrointestinal disorders: Diarrhoea, vomiting, abdominal pain, dysgeusia.
General disorders and administration site conditions: Pyrexia.
Hepatobiliary disorders: Jaundice.
Investigations: Increased ALT and AST.
Nervous system disorders: Dizziness, headache.
Renal and urinary disorders: Haemoglobinuria, acute renal failure.
Respiratory, thoracic and mediastinal disorders: Rhinitis, cough.
Vascular disorders: Hypotension, phlebitis.
|
|
Drug Interactions
Strong UGT inhibitors (e.g. axitinib, imatinib, diclofenac, vandetanib) may increase the plasma concentration of DHA, the active metabolite of artesunate. Nevirapine, ritonavir, or strong UGT inducers (e.g. carbamazepine, phenytoin, rifampicin) may decrease the plasma concentration of DHA, resulting in reduced or loss of efficacy.
|
|
CIMS Class
|
|
ATC Classification
P01BE03 - artesunate ; Belongs to the class of artemisinin and derivative antimalarials.
|
